If the EMA follows the CHMP’s advice, Zynquista will become the second SGLT-acting drug to be approved for use alongside insulin in type 1 diabetes after AstraZeneca’s SGLT2 inhibitor Forxiga ...
BeiGene's TEVIMBRA expands for cancer treatment, and BRUKINSA sales soar 107%. See why BGNE stock presents upside potential ...
Zacks.com on MSN23d
Novartis Gets CHMP Recommendation for Kisqali in Broader PopulationNovartis NVS announced that the Committee for Medicinal Products for Human Use (“CHMP”) of the European Medicines Agency (EMA ...
On October 18 th (CET), the CHMP issued a recommendation for approval, further advancing DMB-3115’s journey toward the European Union. The CHMP evaluates medicinal products based on scientific ...
You have permission to edit this article. Edit Close Activate Subscribe My Account Logout Login/Register ...
BeiGene (BGNE) announced that the Committee for Medicinal Products for Human Use – CHMP – of the European Medicines Agency issued positive opinions recommending an extended authorization for ...
"Together with the recent FDA approval and late-breaking NATALEE data presented at ESMO, today's positive CHMP recommendation further reinforces the differentiated profile of Kisqali as a new ...
WARREN, N.J., Oct. 18, 2024 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) announced today that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback